近年承担多项临床科研课题和国际国内抗癌新药临床试验。

在研课题：

1.      局级课题：《转移性乳腺癌精准诊疗关键技术与临床应用研究》中国医学科学院医学与健康科技创新工程——重大协同创新项目（2021-I2M-1-014）

2.      院级课题：《BRCAness状态对HER2阴性乳腺癌新辅助治疗后未达病理完全缓解（pCR）患者疗效及预后预测作用》肿瘤内科重点学科研究基金

3.      横向课题：《一项评估艾日布林联合贝伐珠单抗治疗多线治疗后转移性乳腺癌的有效性和安全性的单中心II期研究》吴阶平医学基金会临床科研专项资助基金 

4.      横向课题：《HER2阳性早期乳腺癌预后模构建的多中心临床研究》中国抗癌协会—HER2靶点中国科研基金

1. Wang J, Sun T, Ouyang Q, Han Y, Xu B. Aphase Ib study of TQB2450 plus anlotinib in patients with advancedtriple-negative breast cancer. iScience. 2023 May 13;26(6):106876.

2. Wang J, Cai L, Song Y, Sun T, Tong Z,Teng Y, Li H, Ouyang Q, Chen Q, Cui S, Yin Y, Liao N, Sun Q, Feng J, Wang X, XuB. Clinical efficacy of fulvestrant versus exemestane as first-line therapiesfor Chinese postmenopausal oestrogen-receptor positive /human epidermal growthfactor receptor 2 -advanced breast cancer (FRIEND study). Eur J Cancer. 2023May;184:73-82.

3. Han Y, Wang J, Xu B. CytotoxicLymphocyte-Related Gene Signature in Triple-Negative Breast Cancer. J Pers Med.2023 Feb 28;13(3):457.

4. Wang Y, Xu H, Han Y, Wu Y, Sa Q, Wang J.Identifying the optimal therapeutics for patients with hormonereceptor-positive, HER2-positive advanced breast cancer: a systematic reviewand network meta-analysis. ESMO Open. 2023 Apr 19;8(3):101216.

5. Wang Y, Xu H, Han Y, Wu Y, Wang J.Comparative Efficacy of Tyrosine Kinase Inhibitors and Antibody-Drug Conjugatesin HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: ASystematic Review and Network Meta-Analysis. Cancers (Basel). 2022 Jul11;14(14):3372.

6. Xu H, Han Y, Wu Y, Wang Y, Wang J, Xu B.Clinicopathological characteristics and prognosis of microinvasive breastcancer: A population-based analysis. Cancer Med. 2022 Dec;11(23):4501-4512.

7. Xu H, Han Y, Wu Y, Wang Y, Li Q, ZhangP, Yuan P, Luo Y, Fan Y, Chen S, Cai R, Li Q, Ma F, Xu B, Wang J.Clinicopathological Characteristics and Prognosis of HER2-Low Early-StageBreast Cancer: A Single-Institution Experience. Front Oncol. 2022 Jun 16;12:906011.

8. Han Y, Wang J, Wu Y, Xu H, Wang Y, Xu B.Optimal Choice as First-Line Therapy for Patients with Triple-Negative BreastCancer: A Bayesian Network Meta-Analysis. Curr Oncol. 2022 Nov25;29(12):9172-9180.

9. Han Y, Wu Y, Xu H, Wang J, Xu B. Theimpact of hormone receptor on the clinical outcomes of HER2-positive breastcancer: a population-based study. Int J Clin Oncol. 2022 Apr;27(4):707-716.

10. Wu Y, Han Y, Li Q, Zhang P, Yuan P, LuoY, Fan Y, Chen S, Cai R, Li Q, Xu H, Wang Y, Ma F, Wang J, Xu B. Predictivevalue of topoisomerase II alpha protein for clinicopathological characteristicsand prognosis in early breast cancer. Breast Cancer Res Treat. 2022Jun;193(2):381-392.

11. Xu H, Wang Y, Han Y, Wu Y, Wang J, XuB. CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormonereceptor-positive, HER2-negative metastatic breast cancer: An updatedsystematic review and network meta-analysis of 28 randomized controlled trials.Front Oncol. 2022 Aug 24;12:956464.

12. Han Y, Wang J, Xu B. TumorMicroenvironment Subtypes and Immune-Related Signatures for the Prognosis ofBreast Cancer. Biomed Res Int. 2021;2021:6650107.

13. Han Y, Wang J, Xu B. Cutaneous adverseevents associated with immune checkpoint blockade: A systematic review andmeta-analysis. Crit Rev Oncol Hematol. 2021 Jun 2;163:103376.

14. Han Y, Wang J, Xu B. Novel biomarkersand prediction model for the pathological complete response to neoadjuvanttreatment of triple-negative breast cancer. J Cancer. 2021 Jan 1;12(3):936-945.

15. Han Y, Wang J, Wang Z, Xu B. Sex-BasedHeterogeneity in the Clinicopathological Characteristics and Prognosis ofBreast Cancer: A Population-Based Analysis. Front Oncol. 2021 Feb 24;11:642450.

16. Han Y, Wang J, Sun Y, Yu P, Yuan P, MaF, Fan Y, Luo Y, Zhang P, Li Q, Cai R, Chen S, Li Q, Xu B. Prognostic Model andNomogram for Estimating Survival of Small Breast Cancer: A SEER-based Analysis.Clin Breast Cancer. 2020 Nov 13:S1526-8209(20)30290-1.

17. Wu Y, Han Y, Yu P, Ouyang Q, Yan M,Wang X, Hu X, Jiang Z, Huang T, Tong Z, Wang S, Yin Y, Li H, Yang R, Yang H,Teng Y, Sun T, Cai L, Li H, Chen X, He J, Liu X, Yang S, Qiao Y, Fan J, Wang J,Xu B. Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: ANation-Wide Multicenter Epidemiological Study in China. Front Oncol. 2021 Feb11;10:599604.

18. Han Y, Wang J, Wang Z, Xu B.Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in womenwith hormone receptor-positive, HER2-negative metastatic breast cancer: asystematic review and network meta-analysis. Curr Probl Cancer. 2020Dec;44(6):100606.

19. Han Y, Wang J, Wang Z, et al.Clinicopathological characteristics and prognosis of squamous cell carcinoma ofthe breast: A population-based analysis. Cancer Control. 2021; 28: 1-9.